CJC-1295 (no DAC) (CJC)

Modified Growth Hormone Releasing Factor (1-29) that provides more stable GH release when combined with GHRPs. Also known as Mod GRF 1-29.

Key Data

Research Status

Clinical trials

Half-Life

30 minutes

Administration

Subcutaneous injection

Typical Dosage

100-200 mcg

Mechanism of Action

GHRH receptor agonist that stimulates pituitary to release GH in a pulsatile manner, synergizes with GHRPs.

Reported Benefits

• Enhanced GH release
• Improved body composition
• Enhanced recovery
• Better sleep
• Anti-aging effects

All information is presented for Research Use Only (RUO). Not medical advice.